H.C. Wainwright Downgrades Acelyrin Inc (SLRN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St climbs after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Acelyrin Inc (SLRN) PT Lowered to $6 at Citi
August 14, 2024 9:25 AM EDTCiti analyst Samantha Semenkow lowered the price target on Acelyrin Inc (NASDAQ: SLRN) to $6.00 (from $8.00) while maintaining a Neutral rating.
The analyst comments "Acelyrin announced a strategic reprioritization to focus resources on development of lonigutamab (anti-IGFR1) in thyroid eye disease. The company will... More
